Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mecano growth factor peptides and their use

A growth factor, mechanical technology, applied in the direction of insulin-like growth factor, hormone peptide, specific peptide, etc., can solve the problem of expression decline and so on

Inactive Publication Date: 2008-11-05
UCL BUSINESS PLC +1
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, Hill and Golds pink (2003) have demonstrated that in the rat tibialis anterior muscle, MGF is rapidly expressed in response to mechanical injury by electrical stimulation or injection of bupivacaine, but its expression levels then decline within a few days. inner drop

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mecano growth factor peptides and their use
  • Mecano growth factor peptides and their use
  • Mecano growth factor peptides and their use

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0152] Preparation of Polypeptides or Extended Polypeptides of the Invention

[0153] Polypeptides or extended polypeptides of the invention can be prepared using standard techniques. In general, they can be obtained by standard peptide synthesis techniques and, if desired, suitable chemical modifications (eg pegylation) of the resulting amino acid sequences can be carried out. In the absence of D-amino acids, polypeptides and extended polypeptides can also be obtained by recombinant expression in host cells from appropriate coding DNA by standard techniques.

[0154] It can also be isolated and purified to any desired degree using standard techniques. Polypeptides or extended polypeptides of the invention will usually be completely or partially isolated or purified. The preparation of the isolated polypeptide or the extended polypeptide may be any preparation as long as the preparation contains the polypeptide or the extended polypeptide at a higher concentration than the p...

Embodiment

[0170] 1. Peptides

[0171] 1.1 Peptides of Examples 2, 3, 4 and 6

[0172] The peptide used in Examples 2, 3, 4 and 6 has the sequence of SEQ ID NO: 15, wherein the penultimate arginine in the native sequence (see SEQ ID NO: 1, 2 and 27) is replaced by histidine and by replacing the naturally occurring L-arginine with D-arginine at positions 14 and 15, the N-terminus is covalently attached to a polyethylene glycol (PEG) derivative via a succinic acid bridge ( O'O-bis(2-aminopropyl) polyethylene glycol 1900) (Jeffamine), and C-terminal amidation to stabilize the native sequence.

Embodiment 5

[0174] The peptide of Example 5 was purchased from Alta Bioscience, Birmingham, UK and synthesized by standard techniques using a peptide synthesizer. These peptides are non-pegylated, free of L-D conversion and C-terminal amidation.

[0175] In addition, a peptide corresponding to the peptide in 1.1 above with the same L-D conversion but without PEGylation was also tested for stability (see 5.2.3 below). This peptide is synthesized by standard techniques using a peptide synthesizer. The resulting product was purified by HPLC and analyzed by MALDI-MS.

[0176] 1.3 Peptides of Example 7

[0177] 1.3.1 Peptides of Example 7.1

[0178] The peptide of Example 7.1 has an 8 amino acid sequence, Gly-Ser-Thr-Phe-Glu-Glu-His-Lys (SEQ ID NO: 33), with modifications to improve stability. exist Figure 8 In the peptide called DMGF in , stabilization can be achieved by N-terminal PEGylation in 1.1 above. exist Figure 8 In a peptide called CMGF in , stabilization can be achieved by ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to biologically active polypeptides derived from the E peptide that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E peptide.

Description

technical field [0001] The present invention relates to biologically active polypeptides derived from the E-domain forming the C-terminus of the mechano growth factor (MGF) known as a splice variant of insulin-like growth factor I (IGF-I) . These peptides have been modified to increase their stability compared to naturally occurring E domain peptides Background technique [0002] Mammalian IGF-I polypeptides have many isoforms that arise as a result of alternative mRNA splicing. In general, there are two types of isoforms, hepatic isoforms and non-hepatic isoforms. Hepatic isoforms may be expressed in the liver or other organs, but if expressed in other organs, are also equivalent to those isoforms expressed in the liver. The hepatic isoform has systemic effects and is the predominant isoform in mammals. Non-hepatic isoforms are less common and some are believed to have autocrine / paracrine effects. The MGF isoforms involved in the present invention are the latter. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/65A61K38/30
CPCC07K14/65A61K38/00A61P1/04A61P3/10A61P9/00A61P9/04A61P9/10A61P11/00A61P13/02A61P17/02A61P21/00A61P21/04A61P25/00A61P25/16A61P25/28A61P25/32A61P29/00A61P31/18A61P35/00Y02A50/30
Inventor 杰弗里·戈德斯宾克杨士钰P·戈德斯宾克
Owner UCL BUSINESS PLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com